An Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of SZ1003 Injection in Patients With Advanced Hepatocellular Carcinoma
Latest Information Update: 16 Oct 2025
At a glance
- Drugs SZ 1003 (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Guangdong ProCapZoom Biosciences
Most Recent Events
- 16 Oct 2025 New trial record